Skip to content

Author

Chang-Ning Wang

We have 4 of 55 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Development of a Potent and Isoform-Selective HDAC11 Inhibitor with Anti-Tumor Efficacy against Non-Small Cell Lung Cancer

Targeting histone deacetylase 11 (HDAC11) represents a promising therapeutic strategy, yet developing selective inhibitors for solid tumors remains a formidable challenge. Herein, we describe the rational lead optimization of a novel series of indole-based hydroxamic acids. Guided by our previous lead PB94, a systema...

Xin-Yu Yang, Xin Li, Rui Huang et al. · 0 citations
Open access Sep 2026

Neuroimaging of indoleamine 2,3-dioxygenase 1 (Ido1) in Alzheimer's disease: Development of a novel 18F-labeled PET tracer

A novel PET tracer, [18F]XW-032, was developed via ruthenium-mediated deoxyfluorination and effectively visualized regional IDO1 heterogeneity in the AD brain, positioning it as a potent molecular tool for early AD diagnosis and for monitoring the efficacy of IDO1-targeted therapeutic interventions.

Hua Cheng, Nilay S. Narayan, Yong-Le Wang et al. · 0 citations
Sep 2026

Discovery of a brain penetrant NLRP3 inflammasome inhibitor that reduces neuropathic pain in mice

Treatment of AD patient-derived hiPSC glia cells including microglia and astrocytes and neuropathic pain mice with 22 led to suppression of NLRP3 expression and decreased pain and pain-like behavior, supporting the translational promise of this compound and analogs from this chemotype.

Yi-Ming Xu, J. Namme, Liuyue Yang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.